De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
EyePoint Pharmaceuticals Toekomstige groei
Future criteriumcontroles 2/6
EyePoint Pharmaceuticals zal naar verwachting groeien in winst en omzet met respectievelijk 3.1% en 43.3% per jaar. De winst per aandeel zal naar verwachting groeien met 6.4% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting -107% zijn.
Belangrijke informatie
3.1%
Groei van de winst
6.4%
Groei van de winst per aandeel
| Pharmaceuticals winstgroei | 23.7% |
| Inkomstengroei | 43.3% |
| Toekomstig rendement op eigen vermogen | -107.0% |
| Dekking van analisten | Good |
| Laatst bijgewerkt | 16 Sep 2024 |
Recente toekomstige groei-updates
Recent updates
EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Intrinsic Value Is Potentially 38% Above Its Share Price
Sep 13
EyePoint Pharmaceuticals - After A Tough 2024 To Date, Is It Time To 'Buy The Dip' (Rating Upgrade)
Aug 29These Analysts Think EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Sales Are Under Threat
Aug 15EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Aug 09Some Confidence Is Lacking In EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) As Shares Slide 27%
Jun 19EyePoint's Setback In NPDR Does Not Bode Well For DME (Rating Downgrade)
May 06More Unpleasant Surprises Could Be In Store For EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Shares After Tumbling 26%
Mar 31EyePoint Pharmaceuticals: Innovating Eye Treatment, Yet A 'Hold' At This Time
Feb 20Subdued Growth No Barrier To EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) With Shares Advancing 41%
Feb 05Is EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Trading At A 28% Discount?
Jan 29Optimistic Investors Push EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Up 194% But Growth Is Lacking
Dec 18These Analysts Think EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Sales Are Under Threat
Dec 13Calculating The Fair Value Of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
May 14Optimistic Investors Push EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Up 84% But Growth Is Lacking
Apr 17EyePoint Pharmaceuticals: Key Player In The Long-Acting Wet AMD Space
Aug 30Health Check: How Prudently Does EyePoint Pharmaceuticals (NASDAQ:EYPT) Use Debt?
Jul 16EyePoint Pharma announces 12-month phase 1 data for its treatment for eye disorder wAMD
Jul 15Health Check: How Prudently Does EyePoint Pharmaceuticals (NASDAQ:EYPT) Use Debt?
Mar 06EyePoint Pharmaceuticals (NASDAQ:EYPT) Is Using Debt Safely
Sep 24Estimating The Fair Value Of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
Apr 02Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2026 | 8 | -217 | -169 | -184 | 9 |
| 12/31/2025 | 14 | -179 | -142 | -156 | 12 |
| 12/31/2024 | 41 | -120 | -121 | -105 | 12 |
| 6/30/2024 | 50 | -87 | -94 | -90 | N/A |
| 3/31/2024 | 50 | -79 | -17 | -12 | N/A |
| 12/31/2023 | 46 | -71 | -2 | 2 | N/A |
| 9/30/2023 | 43 | -100 | 9 | 12 | N/A |
| 6/30/2023 | 37 | -106 | 12 | 14 | N/A |
| 3/31/2023 | 40 | -102 | -64 | -62 | N/A |
| 12/31/2022 | 41 | -102 | -67 | -65 | N/A |
| 9/30/2022 | 42 | -78 | -71 | -69 | N/A |
| 6/30/2022 | 41 | -77 | -64 | -64 | N/A |
| 3/31/2022 | 39 | -67 | -55 | -55 | N/A |
| 12/31/2021 | 37 | -58 | -50 | -50 | N/A |
| 9/30/2021 | 33 | -54 | -28 | -28 | N/A |
| 6/30/2021 | 39 | -42 | -19 | -19 | N/A |
| 3/31/2021 | 34 | -44 | -14 | -13 | N/A |
| 12/31/2020 | 34 | -45 | -15 | -14 | N/A |
| 9/30/2020 | 36 | -40 | -32 | -32 | N/A |
| 6/30/2020 | 23 | -52 | -48 | -48 | N/A |
| 3/31/2020 | 26 | -51 | -60 | -60 | N/A |
| 12/31/2019 | 20 | -57 | -57 | -57 | N/A |
| 9/30/2019 | 14 | -58 | -56 | -56 | N/A |
| 6/30/2019 | 12 | -75 | -53 | -53 | N/A |
| 3/31/2019 | 6 | -98 | -42 | -42 | N/A |
| 12/31/2018 | 5 | -86 | -34 | -33 | N/A |
| 9/30/2018 | 3 | -80 | -28 | -28 | N/A |
| 6/30/2018 | 3 | -53 | -22 | -22 | N/A |
| 3/31/2018 | 3 | -25 | N/A | -20 | N/A |
| 12/31/2017 | 3 | -23 | N/A | -20 | N/A |
| 9/30/2017 | 8 | -17 | N/A | -20 | N/A |
| 6/30/2017 | 8 | -18 | N/A | -20 | N/A |
| 3/31/2017 | 7 | -19 | N/A | -20 | N/A |
| 12/31/2016 | 7 | -19 | N/A | -20 | N/A |
| 9/30/2016 | 1 | -24 | N/A | -18 | N/A |
| 6/30/2016 | 2 | -22 | N/A | -16 | N/A |
| 3/31/2016 | 2 | -20 | N/A | -15 | N/A |
| 12/31/2015 | 2 | -20 | N/A | -15 | N/A |
| 9/30/2015 | 2 | -19 | N/A | 10 | N/A |
| 6/30/2015 | 27 | 6 | N/A | 10 | N/A |
| 3/31/2015 | 26 | 8 | N/A | 11 | N/A |
| 12/31/2014 | 28 | 10 | N/A | 13 | N/A |
| 9/30/2014 | 28 | 11 | N/A | -11 | N/A |
| 6/30/2014 | 3 | -13 | N/A | -11 | N/A |
| 3/31/2014 | 4 | -13 | N/A | -11 | N/A |
| 12/31/2013 | 2 | -14 | N/A | -11 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachting is dat EYPT de komende 3 jaar verliesgevend zal blijven.
Winst versus markt: De verwachting is dat EYPT de komende 3 jaar verliesgevend zal blijven.
Hoge groeiwinsten: De verwachting is dat EYPT de komende 3 jaar verliesgevend zal blijven.
Omzet versus markt: De omzet van EYPT ( 43.3% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.7% per jaar).
Hoge groei-inkomsten: De omzet van EYPT ( 43.3% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Er wordt voorspeld dat EYPT binnen 3 jaar verliesgevend zal zijn.